Phase III Study of YM178: A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multi-center Study in Subjects With Symptoms of Overactive Bladder.

Trial Profile

Phase III Study of YM178: A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multi-center Study in Subjects With Symptoms of Overactive Bladder.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Feb 2017

At a glance

  • Drugs Mirabegron (Primary) ; Tolterodine
  • Indications Overactive bladder
  • Focus Registrational; Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 01 Apr 2013 Status changed from active, no longer recruiting to completed as reported by Clinical Trials Registry - India record.
    • 28 Jul 2011 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov
    • 28 Jul 2011 Planned end date changed from 1 Jan 2011 to 1 Sep 2011 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top